Loading…
Loading…
Tender Value
Refer Docs
Closing Date
4 Dec 2025, 11:30 amClosed
Single Packet
Normal Tender
No
Itemwise/Consigneewise
Lowest to Highest
CONSIGNEE
Expenditure
General
MEDICAL
2 conditions
It is PAC item of M/s. Novartis pharma A/G Switzerland Its marketing agent is M/s.Novartis health care pvt ltd india. Item is reserved to be procured from M/s. Novartis pharma A/G Switzerland through Its marketing agent M/s. Novartis pharma A/G Switzerland.
Product will be regarded as one salt. Various strength of same will be regarded as one product as per para 2.1.3 of DPP 2014/RS(G)/779/13 dated 03.02.2015
26 conditions · 7 needing a document upload
Please write/mention name & address of the marketing/importing agency with details of authorized distributor.
The firm will mention name(s) of specific stores of area where such drug is being sold in the open market. The zone will undertake random 5% check to establish that the product quoted by the firm is actually available in the store(s) mentioned by the firm. Further, if at the point of time of inspection such drug is not available in the Store (s) due sale of available stock, the retailer will be asked to provide a copy of purchase memo/supply order of the product from the firm.
The bidders are required to quote rates for one tablet/capsule.
The bidder confirms that rates and other financial terms quoted in relevant columns of financial bid will only be ruling terms for acceptance, and such terms quoted anywhere else should be ignored. (Denial of this condition not recommended).
Please enter the percentage of local content in the material being offered. Please enter 0 for fully imported items, and 100 for fully indigenous items. The definition and calculation of local content shall be in accordance with the Make in India policy as incorporated in the tender conditions.
By consignee after receipt.
Make in India policy will be applicable as per the conditions of the tender documents attached & it is in line with the guidelines issued by Railway Board vide Letter No. 2020/RS(GY779/9/PL.2 dated 03.12.2020. The purchase will be made from only those firms who have more than minimum local content as prescribed in the make in India policy. However this policy will not be applicable for small purchases having value less than 5 Lakh or items in included MII exemption list issued by ministry of finance (for tender invited within validity of exemption )
Please enter the percentage of local content in the material being offered. Please enter 0 for fully imported items, and 100 for fully indigenous items. The definition and calculation of local content shall be in accordance with the Make in India policy as incorporated in the tender conditions.
In case of rate contracts, the quantities indicated in the tender are mere estimates. The figures indicated in the tender do not constitute any commitment on part of the railway to purchase any of the articles, in the quantities shown or in any quantity whatsoever. Railway does not bind itself to purchase all or any quantities mentioned in the tender.
1 location across Rajasthan · 50 Numbers total
Brolucizumab 120mg /ml Vial injection
82253908C~NWR
82253908C
PAC - Indigenous
Goods
Jaipur, Rajasthan
₹0
Exempted
4 Dec 2025
26 Nov 2025
1 item · 50 Numbers total
Brolucizumab 120mg /ml Vial injection ]
| Delivery Location | State | Quantity |
|---|---|---|
| CENTRAL HOSPITAL JAIPUR, NWR | Rajasthan | 50.00 Numbers |
| Total | 50 Numbers | |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
HTML
nit.pdf
NIT
5600389.pdf
ATTACHMENT
5445255.pdf
ATTACHMENT
5342849.pdf
ATTACHMENT
5446958.pdf
ATTACHMENT
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .